TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20
<p><strong>Objectives</strong></p> <p>About half of RA patients treated with TNFα inhibitors either do not respond or lose their initial therapeutic response over time. The clinical response is measured by reduction in DAS28, which primarily reflects inflammation. Howev...
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado: |
Oxford University Press
2020
|